Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/307254
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology |
Autor: | Calleja, José Luis; Rivera-Esteban, Jesús; Aller, Rocío; Hernández-Conde, Marta; Abad, Javier; Pericás Pulico, Juan Manuel; Benito, Hugo G.; Serra, Miguel Ángel; Escudero, Amparo; Ampuero, Javier CSIC ORCID; Lucena, Ana; Sánchez-Torrijos, Yolanda CSIC; Arias-Loste, María Teresa; Iruzubieta, Paula; Romero-Gómez, Manuel CSIC ORCID CVN; Augustin, Salvador; Crespo, Javier CSIC | Palabras clave: | Hepatic fibrosis Liver biopsy Non-alcoholic steatohepatitis Transient elastography |
Fecha de publicación: | ago-2022 | Editor: | John Wiley & Sons | Citación: | Liver International 42(8): 1783-1792 (2022) | Resumen: | [Background & Aims] Non-alcoholic fatty liver disease (NAFLD) has become a major public health problem, but the prevalence of fibrosis associated with non-alcoholic steatohepatitis (NASH) is largely unknown in the general population. This study aimed to provide an updated estimation of the prevalence of NASH fibrosis in Spain. [Methods] This was an observational, retrospective, cross-sectional, population-based study with merged data from two Spanish datasets: a large (N = 12 246) population-based cohort (ETHON), including transient elastography (TE) data, and a contemporary multi-centric biopsy-proven NASH cohort with paired TE data from tertiary centres (N = 501). Prevalence for each NASH fibrosis stage was estimated by crossing TE data from ETHON dataset with histology data from the biopsy-proven cohort. [Results] From the patients with valid TE in ETHON dataset (N = 11 440), 5.61% (95% confidence interval [95% CI]: 2.53-11.97) had a liver stiffness measurement (LSM) ≥ 8 kPa. The proportion attributable to NAFLD (using clinical variables and Controlled Attenuation Parameter) was 57.3% and thus, the estimated prevalence of population with LSM ≥ 8 kPa because of NAFLD was 3.21% (95% CI 1.13–8.75). In the biopsy-proven NASH cohort, 389 patients had LSM ≥ 8 kPa. Among these, 37% did not have significant fibrosis (F2-4). The estimated prevalence of NASH F2-3 and cirrhosis in Spain's adult population were 1.33% (95% CI 0.29–5.98) and 0.70% (95% CI 0.10–4.95) respectively. [Conclusions] These estimations provide an accurate picture of the current prevalence of NASH-related fibrosis in Spain and can serve as reference point for dimensioning the therapeutic efforts that will be required as NASH therapies become available. |
Versión del editor: | https://doi.org/10.1111/liv.15323 | URI: | http://hdl.handle.net/10261/307254 | DOI: | 10.1111/liv.15323 | ISSN: | 1478-3223 | E-ISSN: | 1478-3231 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Prevalence_estimation_Calleja.pdf | 591,11 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
4
checked on 18-mar-2024
SCOPUSTM
Citations
8
checked on 21-mar-2024
WEB OF SCIENCETM
Citations
7
checked on 25-feb-2024
Page view(s)
31
checked on 28-mar-2024
Download(s)
19
checked on 28-mar-2024